Lisa M Daniels1, Urshila Durani2, Jason N Barreto3, John C O'Horo4, Mustaqeem A Siddiqui5, John G Park6, Pritish K Tosh4. 1. Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, 5665 Peachtree Dunwoody Rd, Atlanta, GA, 30342, USA. lisa.daniels@emory.edu. 2. Division of Hematology, Division of Medical Oncology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. 3. Department of Pharmacy, Mayo Clinic Rochester, Rochester, MN, USA. 4. Division of Infectious Diseases, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, USA. 5. Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. 6. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Abstract
PURPOSE: To determine if time to antibiotics (TTA) improves outcomes of hospital length of stay, admission to the intensive care unit, and 30-day mortality in adult patients with febrile neutropenia. METHODS: This retrospective cohort study evaluated the impact of time to antibiotic, in the treatment of febrile neutropenia, on hospital length of stay, admission to the intensive care unit, and 30-day mortality. Cases included were patients 18 years or older hospitalized with febrile neutropenia from August 1, 2006 to July 31, 2016. To adjust for other characteristics associated with hospital length of stay, admission to the intensive care unit, and 30-day mortality, a multivariate analysis was performed. RESULTS: A total of 3219 cases of febrile neutropenia were included. The median hospital length of stay was 7.0 days (IQR 4.1-13.3), rate of intensive care unit admission was 13.6%, and 30-day mortality was 6.6%. Multivariate analysis demonstrated time to antibiotics was not associated with hospital length of stay but was associated with admission to the intensive care unit admission and 30-day mortality. Delays in time to antibiotic of up to 3 hours did not impact outcomes. CONCLUSIONS: A shorter time to antibiotic is important in treatment of febrile neutropenia; however, moderate delays in antibiotic administration did not impact outcomes. Further investigation is needed in order to determine if other indicators of infection, in addition to fever, or other supportive management, in addition to antibiotics, are indicated in the early identification and management of infection in patients with neutropenia.
PURPOSE: To determine if time to antibiotics (TTA) improves outcomes of hospital length of stay, admission to the intensive care unit, and 30-day mortality in adult patients with febrile neutropenia. METHODS: This retrospective cohort study evaluated the impact of time to antibiotic, in the treatment of febrile neutropenia, on hospital length of stay, admission to the intensive care unit, and 30-day mortality. Cases included were patients 18 years or older hospitalized with febrile neutropenia from August 1, 2006 to July 31, 2016. To adjust for other characteristics associated with hospital length of stay, admission to the intensive care unit, and 30-day mortality, a multivariate analysis was performed. RESULTS: A total of 3219 cases of febrile neutropenia were included. The median hospital length of stay was 7.0 days (IQR 4.1-13.3), rate of intensive care unit admission was 13.6%, and 30-day mortality was 6.6%. Multivariate analysis demonstrated time to antibiotics was not associated with hospital length of stay but was associated with admission to the intensive care unit admission and 30-day mortality. Delays in time to antibiotic of up to 3 hours did not impact outcomes. CONCLUSIONS: A shorter time to antibiotic is important in treatment of febrile neutropenia; however, moderate delays in antibiotic administration did not impact outcomes. Further investigation is needed in order to determine if other indicators of infection, in addition to fever, or other supportive management, in addition to antibiotics, are indicated in the early identification and management of infection in patients with neutropenia.
Entities:
Keywords:
Fever neutropenia; Hospital utilization; Mortality; Sepsis and septic shock; Time to antibiotic
Authors: E Rivers; B Nguyen; S Havstad; J Ressler; A Muzzin; B Knoblich; E Peterson; M Tomlanovich Journal: N Engl J Med Date: 2001-11-08 Impact factor: 91.245
Authors: Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young Journal: Clin Infect Dis Date: 2002-02-13 Impact factor: 9.079
Authors: Michael K Keng; Elaine A Thallner; Paul Elson; Christine Ajon; Jennifer Sekeres; Candice M Wenzell; David J Seastone; Erika M Gallagher; Catherine M Weber; Marc A Earl; Sudipto Mukherjee; Brad Pohlman; Eric Cober; Virginia B Foster; Joy Yuhas; Matt E Kalaycio; Brian J Bolwell; Mikkael A Sekeres Journal: J Oncol Pract Date: 2015-07-28 Impact factor: 3.840
Authors: Christa Koenig; Christine Schneider; Jessica E Morgan; Roland A Ammann; Lillian Sung; Bob Phillips Journal: Support Care Cancer Date: 2019-07-01 Impact factor: 3.603
Authors: Christa Koenig; Claudia E Kuehni; Nicole Bodmer; Philipp K A Agyeman; Marc Ansari; Jochen Roessler; Nicolas X von der Weid; Roland A Ammann Journal: Sci Rep Date: 2022-08-18 Impact factor: 4.996